Cue Biopharma
Christie Zhang has worked in various roles in the biopharmaceutical industry since 2005. Christie began as a PhD student and Research Technician at UCL in 2005, then moved to Children's Hospital Boston- affiliated with Harvard Medical School in 2013 as a Postdoc Research Fellow. In 2017, they became a Principal Research Associate at FORMA Therapeutics, Inc. In 2018, they joined Elstar Therapeutics Inc. as a Scientist I and was promoted to Scientist II. In 2020, they were promoted again to Principal Scientist at Cue Biopharma.
Christie Zhang received a Doctor of Philosophy (Ph.D.) in Cancer research (Virotherapy) from UCL between 2007 and 2012. Prior to that, they earned a BSc in Biochemistry from Imperial College London between 2002 and 2005.
This person is not in any offices
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.